FDA approves Garzulys (insulin aspart-fsan) as a rapid-acting biosimilar to NovoLog for adult and pediatric patients with diabetes mellitus.

Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...

Kirsty 100units/mL is supplied as a 3 mL single-patient-use prefilled pen as well as a 10 mL multiple-dose vial. The approval of insulin aspart-xjhz was supported by a comprehensive data package that ...

NovoLog (insulin aspart) is a fast-acting insulin used for diabetes treatment. It’s injected 5 to 10 minutes before meals. It may be prescribed with other insulins or oral diabetes drugs. NovoLog ...

NovoLog (insulin aspart) is a prescription medication used to manage blood sugar levels in people with type 1 or type 2 diabetes. NovoLog dosage varies based on individual factors such as the type of ...

Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

NovoLog (insulin aspart) and Humalog (insulin lispro) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in certain ...

NovoLog is a mealtime (rapid-acting) insulin. It’s a brand-name form of insulin aspart. For type 1 diabetes, you’ll typically inject NovoLog before your meals throughout the day. For type 2 diabetes, ...

(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S. LLC's Merilog (insulin-aspart-szjj) becomes the first rapid-acting insulin biosimilar product to get its approval ...